Recommended

Learn how to optimize antibody leads in early drug discovery in this upcoming webinar – register today
Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

New system enables improved pre-clinical testing of heart drugs

Posted: 26 July 2019 | | No comments yet

Researchers have extended the life of heart segments from 24 hours to six days, enabling pre-clinical trials to experiment on these new models for longer periods of time.

Heart slices in the physiological biomimetic culture system developed at UofL (credit: University of Louisville).

An easily reproducible system that enables scientists to keep slices of human hearts alive for longer has been developed, allowing more extensive testing of new drugs and gene therapies.

This new biomimetic culture system mimics the environment of a living organ through continuous electrical stimulation and oxygenation, maintaining viability and functionality of the heart segments for six days. As the previous timescale was no more than 24 hours, the developers say the extended time will enable improved pre-clinical testing of new drugs for effectiveness and toxicity.

“This new method maintains fully functional human heart slices for six days in the culture environment,” said Dr Tamer M A Mohamed, from the University of Louisville, who led the research. “This facilitates testing efficacy of heart failure therapeutics and cardiotoxins on human heart tissue with no need for a living human.” 

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

The system provides access to the complete three-dimensional multicellular system that reflects the heart’s functional and structural condition in a living person.

“This system will save time and costs of clinical trials during Phase I research, which includes testing for toxicity and proof of efficacy,” Mohamed continued. “In addition to drugs, we have demonstrated the system’s effectiveness in testing gene therapy.”

The study, ‘A Physiological Biomimetic Culture System for Pig and Human Heart Slices’ was published online in Circulation Research, a publication of the American Heart Association.